Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,876 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Cyclophosphamide, epirubicin, and Fluorouracil versus dose-dense epirubicin and cyclophosphamide followed by Paclitaxel versus Doxorubicin and cyclophosphamide followed by Paclitaxel in node-positive or high-risk node-negative breast cancer.
Burnell M, Levine MN, Chapman JA, Bramwell V, Gelmon K, Walley B, Vandenberg T, Chalchal H, Albain KS, Perez EA, Rugo H, Pritchard K, O'Brien P, Shepherd LE. Burnell M, et al. J Clin Oncol. 2010 Jan 1;28(1):77-82. doi: 10.1200/JCO.2009.22.1077. Epub 2009 Nov 9. J Clin Oncol. 2010. PMID: 19901117 Free PMC article. Clinical Trial.
Prognostic associations of 25 hydroxy vitamin D in NCIC CTG MA.21, a phase III adjuvant randomized clinical trial of three chemotherapy regimens in high-risk breast cancer.
Lohmann AE, Chapman JA, Burnell MJ, Levine MN, Tsvetkova E, Pritchard KI, Gelmon KA, O'Brien P, Han L, Rugo HS, Albain KS, Perez EA, Vandenberg TA, Chalchal HI, Sawhney RP, Shepherd LE, Goodwin PJ. Lohmann AE, et al. Breast Cancer Res Treat. 2015 Apr;150(3):605-11. doi: 10.1007/s10549-015-3355-x. Epub 2015 Apr 2. Breast Cancer Res Treat. 2015. PMID: 25833209 Clinical Trial.
Prognostic and predictive investigation of PAM50 intrinsic subtypes in the NCIC CTG MA.21 phase III chemotherapy trial.
Liu S, Chapman JA, Burnell MJ, Levine MN, Pritchard KI, Whelan TJ, Rugo HS, Albain KS, Perez EA, Virk S, Barry G, Gao D, O'Brien P, Shepherd LE, Nielsen TO, Gelmon KA. Liu S, et al. Breast Cancer Res Treat. 2015 Jan;149(2):439-48. doi: 10.1007/s10549-014-3259-1. Epub 2015 Jan 1. Breast Cancer Res Treat. 2015. PMID: 25552364 Clinical Trial.
Optimizing the use of virtual care in primary care.
Walji S, Rozmovits L, O'Brien P, Loi A, Rawji A. Walji S, et al. Among authors: o brien p. Can Fam Physician. 2024 May;70(5):322-324. doi: 10.46747/cfp.7005322. Can Fam Physician. 2024. PMID: 38744504 Free article. No abstract available.
Considerations for the Identification and Conveyance of Clinical Pathology Findings in Preclinical Toxicity Studies: Results From the 9th ESTP International Expert Workshop.
Arndt T, Keresztes M, Olivier B, Boone L, Chanut F, Ennulat D, Evans E, Freyberger A, Johannes S, Kuper CF, Maliver P, O'Brien P, Ramaiah L, Roman I, Strauss V, Vinken P, Walker D, Winter M, Pohlmeyer-Esch G, Tomlinson L. Arndt T, et al. Among authors: o brien p. Toxicol Pathol. 2024 Apr 25:1926233241245108. doi: 10.1177/01926233241245108. Online ahead of print. Toxicol Pathol. 2024. PMID: 38661116
2,876 results